Viking Therapeutics VKTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | ||
| $344.96M+239% | $101.64M+59.3% | $63.81M+17.6% | $54.23M+20.6% | ||
| $48.39M-1.8% | $49.28M+33.1% | $37.02M+130% | $16.12M+50.6% | ||
| $393.34M+161% | $150.92M+49.7% | $100.83M+43.3% | $70.36M+26.4% | ||
| $393.34M+161% | $150.92M+49.7% | $100.83M+43.3% | $70.36M+26.4% | ||
| -$393.34M-161% | -$150.92M-49.7% | -$100.83M-43.3% | -$70.36M-26.4% | ||
| $33.7M-17.7% | $40.94M+173% | $15.02M+845% | $1.59M+126% | ||
| $33.7M-17.7% | $40.96M+174% | $14.93M+903% | $1.49M+115% | ||
| $55K-50.9% | $112K— | $0— | —— | ||
| -$359.64M-227% | -$109.96M-28.0% | -$85.9M-24.7% | -$68.87M-25.2% | ||
| -$3.19-219% | -$1.00-8.7% | -$0.92-1.1% | -$0.91-26.4% | ||
| -$3.19-219% | -$1.00-8.7% | -$0.92-1.1% | -$0.91-28.2% | ||
| 449.2M+3.5% | 433.8M+16.8% | 371.6M+20.8% | 307.6M-0.1% | ||
| 449.2M+3.5% | 433.8M+16.8% | 371.6M+20.8% | 307.6M— | ||
| $33.7M-17.7% | $40.94M+173% | $15.02M+845% | $1.59M+126% | ||
| $56K-40.4% | $94K+6.8% | $88K+49.2% | $59K+211% | ||
| -$358.47M-225% | -$110.36M-29.6% | -$85.18M-22.7% | -$69.42M-25.1% | ||
| $47K+121% | -$225K— | —— | —— | ||
| $1.13M+749% | -$174K-123% | $742K— | —— | ||
| $33.7M-17.7% | $40.96M+174% | $14.93M+903% | $1.49M+115% | ||
| $0— | $0— | $0— | $0— | ||
| -$393.34M-161% | -$150.92M-49.7% | -$100.83M-43.3% | -$70.36M-26.4% | ||
| -$393.34M-161% | -$150.92M-49.7% | -$100.83M-43.3% | -$70.36M-26.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's income statement data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.